



Annual Report 2025

Active Trials

Clinical Research
for a Cure Tomorrow

[swisscancerinstitute-jahresbericht.ch](https://www.swisscancerinstitute-jahresbericht.ch)

Trial Name	Trial Title	Disease group	Clinical Phase	CI	CPM
ACHILES	A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-cell lung cancer	Lung	Phase II	Rothschild Sacha	Fehrenbacher Julia
BAYER 22615 SOHO-02	A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations	Lung	Phase III	Rothschild Sacha	Zackel Monika-Krista
CAMBRIA-2	CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degradar) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease	Breast	Phase III	Zürrer Ursina	Musilova Jana
CLL 17	A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinib mono-therapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL)	Leukemias	Phase III	Gregor Michael	Fehrenbacher Julia
CLL 18	A phase 3 multicenter, randomized, prospective, open-label trial of MRD-guided venetoclax/pirtobrutinib vs. fixed-duration venetoclax/pirtobrutinib vs. fixed-duration venetoclax/Obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL)	Leukemias	Phase III	Gregor Michael	Fehrenbacher Julia
DANTE	A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340) – The IKF-DANTE Trial	Gastrointestinal	Phase II/III	Siebenhüner Alexander	Kern Mara
EMCL-Registry	The Registry of the European Mantle Cell Lymphoma study group	Lymphomas	n/a	Fehr Martin	Müller Gisela
EMN30 MajesTEC-4	Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation – The Majestec-4 study	Lymphomas	Phase III	Driessen Christoph	Rentsch Priska
EORTC 10085 PRO	EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG intergroup study	Breast	n/a	Aebi Stefan Paul	Schär Corinne
EORTC PEARLS	A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)	Lung	Phase III	Curioni-Fontecedro Alessandra	Rentsch Priska

Trial Name	Trial Title	Disease group	Clinical Phase	CI	CPM
EORTC-LEGATO	Lomustine with or without reirradiation for first progression of glioblastoma: a randomized phase III study	Central nervous System	Phase III	Le Rhun Emilie	Zackel Monika-Krista
ETOP ADOPT	ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-III B (N2) resectable NSCLC	Lung	Phase III	Schmid Sabine	Rentsch Priska
ETOP AMAZE	ETOP 18-21 AMAZE-lung: A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI	Lung	Phase II	Früh Martin	Rentsch Priska
ETOP ARCH	ETOP 27-23 ARCH: A randomised phase III trial of adjuvant cemiplimab in patients with resected stage II-III A NSCLC who have not received prior adjuvant chemotherapy	Lung	Phase III	Mauti Laetitia	Rentsch Priska
ETOP CHESS	A multicentre single arm phase II trial assessing the efficacy of radical immunotherapy and chemotherapy, stereotactic radiotherapy and surgery in patients with synchronous oligo-metastatic NSCLC	Lung	Phase II	Stahel Rolf A.	Rentsch Priska
ETOP RAISE	ETOP 23-22 RAISE A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.	Lung	Phase II	Jörger Markus	Rentsch Priska
GRAALL 2014	Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years) - Comprising 3 sub-studies according to lineage (2 sub-substudies) GRAALL-2014/B & QUEST substudy Ph-negative B-lineage ALL GRAALL-2014/T & ATRIAL substudy T-ALL GRAAPH-2014 Ph+ ALL	Leukemias	Phase II/III	Chalandon Yves	Fehrenbacher Julia
HD 21	HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD	Lymphomas	Phase III	Moccia Alden	Müller Gisela
HOVON 127/ SAKK 37/16	Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma	Lymphomas	Phase III	Stenner Frank	Fehrenbacher Julia
HOVON 150	A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy	Leukemias	Phase III	Manz Markus G.	Fehrenbacher Julia Moreno Monasterio Patricia

Trial Name	Trial Title	Disease group	Clinical Phase	CI	CPM
HOVON 155	A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in UNFIT (i.e. HCT-CI \geq 3) adult AML and high risk myelodysplasia (MDS) (IPSS-R $>$ 4.5) patients. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT- AML/high-risk MDS patients.	Leukemias	Phase II	Blum Sabine	Fehrenbacher Julia
HOVON 156	HOVON 156 / AMLSG 28-18: A phase 3, multicenter, open-label, randomized, study of Gilteritinib versus Midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy	Leukemias	Phase III	Pabst Thomas	Fehrenbacher Julia Vorburger Corinne
HOVON 173 / EVOLVE-1	EVOLVE-1: Ivosidenib-Azacetydin-Placebo vs Ivosidenib-Azacetydin-Venetoclax in AML with IDH1mut	Leukemias	Phase III	Widmer Corinne	Rentsch Priska
HOVON 177 /EVOLVE-2	EVOLVE-2: Azacetydin/Venetoclax/Placebo vs. Azacetydin/Venetoclax/Placebo AML with NPM1mut or MLL rearrangement	Leukemias	Phase III	Böttcher Steffen	Rentsch Priska
IBCSG 38-10	A randomized phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast	Breast	Phase III	Gruber Günther	Zackel Monika-Krista
IBCSG 48-14 POSITIVE	A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE)	Breast	n/a	Pagani Olivia	Zackel Monika-Krista
IBCSG 50-14 OLYMPIA	A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib vs placebo as adjuvant treatment in patients with high risk germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy	Breast	Phase III	Novak Urban	Zackel Monika-Krista
IBCSG 52-15 PALLAS	PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.	Breast	Phase III	Vetter Marcus	Zackel Monika-Krista
IBCSG 59-19 POLAR	A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer	Breast	Phase III	Aebi Stefan Paul	Zackel Monika-Krista
IBCSG 67-22 PREcoopERA	A Window-of-Opportunity (WOO) trial of giredestrant +/- triptorelin vs. anastrozole +triptorelin in premenopausal pts with ER+/HER2- eBC	Breast	n/a	Dubsky Peter	Zackel Monika-Krista

Trial Name	Trial Title	Disease group	Clinical Phase	CI	CPM
IELSG-37	A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)	Lymphomas	Phase III	Zucca Emanuele	Fehrenbacher Julia
IELSG-47	Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas	Lymphomas	Phase II	Zucca Emanuele	Fehrenbacher Julia
IELSG-48	IELSG-48: Phase 3, interventional, multicentre, open label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma	Lymphomas	Phase III	Rossi Davide	Fehrenbacher Julia
IP-IIO-622_SAKK 69/22	Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter Phase 1b/2a trial in colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients	Developmental Therapeutics	Phase I/II	Jörger Markus	Fehrenbacher Julia
MorningLyte	Phase III randomized, open-label, multinational, multicenter, study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to CD20 Ab plus chemotherapy in subjects with previously untreated high-tumor burden follicular lymphoma.	Lymphomas	Phase III	de Ramon Carmen	Wicki Gwendoline
NX-5948-301	A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degradar, in Adults with Relapsed/Refractory B-cell Malignancies	Lymphomas	Phase I	Stathis Anastasios	Fehrenbacher Julia
PEACE-4	A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer	Urogenital	Phase III	Gillessen Silke	Fehrenbacher Julia
SAKK 01/10	Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma	Urogenital	Phase II	Papachristofilou Alexandros	Schär Corinne
SAKK 01/18	Reduced intensity radiochemotherapy for Stage IIA/B Seminoma. A multicenter, open label phase II trial with two cohorts	Urogenital	Phase II	Papachristofilou Alexandros	Vokálová Lenka
SAKK 06/17	Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A multicenter, single-arm phase II trial	Urogenital	Phase II	Cathomas Richard	Musilova Jana
SAKK 06/19	Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC). A multicenter, single-arm phase II trial.	Urogenital	Phase II	Cathomas Richard	Chiquet Sabrina
SAKK 07/17	Nivolumab in combination with Ipilimumab in patients with metastatic renal cell carcinoma: A multicenter single-arm phase II trial.	Urogenital	Phase II	Stenner Frank	Chiquet Sabrina
SAKK 08/23	Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial	Urogenital	Phase II	Cathomas Richard	Wyss-Neyer Simone Rahel

Trial Name	Trial Title	Disease group	Clinical Phase	CI	CPM
SAKK 15/19	Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (ED-SCLC). A multicenter single arm open label phase II trial	Lung	Phase II	Addeo Alfredo	Wicki Gwendoline
SAKK 16/18	Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial.	Lung	Phase II	Mauti Laetitia	Müller Gisela
SAKK 19/17	First line durvalumab in patients with PD-L1 positive, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial	Lung	Phase II	Mark Michael Thomas	Chiquet Sabrina
SAKK 21/23	NEODOXY: Targeting cancer stem cells with NEOadjuvant DOXYcycline in patients with early ER+/HER2- breast cancer. A prospective, multicenter, single arm, open label phase II trial	Breast	Phase II	Lelièvre Loïc	Vokálová Lenka
SAKK 23/16	Tailored AXillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized open labeled phase III trial.	Breast	Phase III	Weber Walter	Schulz Alexandra
SAKK 23/18	Vacuum assisted biopsy Immediately before Surgery as an Intra- or pre-Operative surrogate for patient response to Neoadjuvant chemotherapy for breast cancer (VISION I)	Breast	n/a	Tausch Christoph	Tschopp Daniel
SAKK 34/17	Ibrutinib lead-in followed by venetoclax plus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter, open-label, phase II trial	Leukemias	Phase II	Rossi Davide	Müller Gisela
SAKK 38/19	Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial	Lymphomas	Phase II	Stathis Anastasios	Musilova Jana
SAKK 38/23	SAKK 38/23 LIBERTY: Liquid biopsy to diagnose and monitor central nervous system (CNS) involvement in high-risk B cell non-Hodgkin lymphoma	Lymphomas	n/a	Lang Noémie	Chiquet Sabrina
SAKK 41/23	Primary and Acquired Resistance to TArgeted treatment in BRAFV600E-mutated metastatic Colorectal cancer (PARTACER-Suisse)	Gastrointestinal	n/a	Fritsch Ralph	Zackel Monika-Krista
SAKK 57/24	Feasibility of Total Neoadjuvant Treatment with HYPeRthermia in patients with high-risk extremity and trunk soft tissue sarcoma (TNT-HYPE): A multicenter, single arm, open label, phase II trial	Sarcomas	Phase II	Stutz Emanuel	Wicki Gwendoline
SAKK 66/17	Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter phase Ib/Ia trial with expansion cohorts in melanoma and soft tissue sarcoma patients	Developmental Therapeutics	Phase I/II	Jörger Markus	Wicki Gwendoline
SAKK 66/22	Intratumoral INT230-6 followed by neoadjuvant immunochemotherapy in patients with early triple-negative breast cancer (TNBC). An open-label randomized two cohort phase 2 clinical trial. INVINCIBLE-4-SAKK	Developmental Therapeutics	Phase II	Zürrer Ursina	Musilova Jana

Trial Name	Trial Title	Disease group	Clinical Phase	CI	CPM
SAKK 70/24 PHENIX	Open-label phase II clinical trial to test the efficacy of the combination of Trimipramine and Atezolizumab with Bevacizumab in patients with recurrent glioblastoma	Central nervous System	Phase II	Hottinger Andreas	Chiquet Sabrina
SAKK 89/24 QoL vs LoL	Assessing medical professionals and cancer patients' preferences for quality of life (QoL) and length of life (LoL) in oncology: Evidence from a pilot study on gastric, prostate and oesophagus cancer	Outcomes Research	n/a	Chevallay Mickael	Vokálová Lenka
SAKK 96/12	Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks – A Non-Inferiority Phase III Trial	Urogenital	Phase III	von Moos Roger	Wyss-Neyer Simone Rahel
SAKK_LuCa 2	SAKK_LuCa 2: Retrospective and prospective registry of patients with metastatic NSCLC harboring typical and atypical EGFR mutations	Lung	n/a	Schmid Sabine	Müller Gisela
SAKK_OvCaR	SAKK_OvCaR: A retrospective and prospective registry of patients with ovarian cancer	Gynecological	n/a	Vetter Marcus	Wyss-Neyer Simone Rahel
salVage	Phase III randomized controlled trial comparing maintenance systemic therapy alone with systemic therapy plus local ablative treatment for patients with advanced stage IV non-small cell lung cancer	Lung	Phase III	Schmitt-Opitz Isabelle	Rexhepaj Albana Wicki Gwendoline
TRIANGLE	Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing Induction in Generalized Mantle Cell Lymphoma – a randomized European MCL Network Trial	Lymphomas	Phase III	Mey Ulrich	Müller Gisela
TROP2 EC	A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy	Gynecological	Phase III	Wampfler Julian	Zackel Monika-Krista